Dear Dr. Finn:

Please refer to your Supplemental New Drug Application (sNDA) dated August 12, 2011, received August 12, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zyrtec® (cetirizine HCl) tablet, 10 mg.

We also refer to your amendment dated January 25, 2012.

This Prior Approval supplemental new drug application provides for two new packaging configurations to be marketed as two stock keeping units (SKUs). The SKUs consist of a 7-count carton and a 7-count immediate container (blister card) and a 14-count carton and two 7-count immediate containers (blister cards).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling, as soon as they are available, but no more than 30 days after they are printed. The final printed labeling (FPL) must be identical to the enclosed labeling (the 7-count immediate container (blister card) label submitted on August 12, 2011 and the 14-count carton label (representative of the 7-count carton label) submitted on January 25, 2012). As representative labeling is not acceptable for FPL, please include the 7-count carton label as part of your FPL submission for S-030. The FPL must be in the “Drug Facts” format (21 CFR 201.66), where applicable.
The final printed labeling should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Labeling for approved NDA 019835/S-30” Approval of this submission by FDA is not required before the labeling is used.

**DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). If you have any questions, call Janice Adams-King, Regulatory Project Manager, at (301) 796-3713.

Sincerely,

{See appended electronic signature page}

Andrea Leonard-Segal, M.D., M.S.
Director
Division of Nonprescription Clinical Evaluation
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE(S):
Carton and Immediate Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANDREA LEONARD SEGAL
03/13/2012